全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
PLOS ONE  2013 

Factors Associated With the Time to Next Attack in Neuromyelitis Optica: Accelerated Failure Time Models With Random Effects

DOI: 10.1371/journal.pone.0082325

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background and Objective Neuromyelitis optica (NMO) is an inflammatory demyelinating disorder of the central nervous system with a relapsing and remitting course. We aimed to identify factors associated with the time to next attack, including the effect of the natural disease course and the diverse treatment regimens, by applying a longitudinal statistical analysis to the individual attacks of each patient. Methods In total, 184 acute attacks among 58 patients with either NMO or NMO spectrum disorder with anti-aquaporin-4 antibody were assessed retrospectively. Patient demographics, clinical characteristics at each attack, and type of treatment during inter-attack periods were assessed. The dependent variable was defined as the time from each attack to the next attack (inter-attack interval). An exponential accelerated failure time model with shared gamma frailty was adapted for statistical analysis. Results A multivariable analysis revealed that the time from each attack to the next attack in NMO increased independently by 1.31 times (95% confidence interval (CI), 1.02–1.67; p = 0.035) with each additional cumulative attack experienced, by 5.34 times (95% CI, 1.57–18.13; p = 0.007) with combined azathioprine treatment and continued oral prednisolone, and by 4.26 times (95% CI, 1.09–16.61; p = 0.037) with rituximab treatment. Conclusion The time to next attack in NMO can increase naturally in the later stages of the disease as the number of cumulative attacks increases. Nevertheless, both combined azathioprine treatment with continued oral prednisolone and rituximab treatment were also associated with a longer time to next attack, independently of the natural disease course of NMO.

References

[1]  Kim W, Kim SH, Kim HJ (2011) New insights into neuromyelitis optica. J Clin Neurol 7: 115-127. doi:10.3988/jcn.2011.7.3.115. PubMed: 22087205.
[2]  Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. (2006) (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66: 1485-1489. doi:10.1212/01.wnl.0000216139.44259.74. PubMed: 16717206.
[3]  Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG (2007) A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 68: 603-605. doi:10.1212/01.wnl.0000254502.87233.9a. PubMed: 17310032.
[4]  Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ et al. (2011) Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77: 659-666. doi:10.1212/WNL.0b013e31822a2780. PubMed: 21813788.
[5]  Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C et al. (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66: 1128-1133. doi:10.1001/archneurol.2009.175. PubMed: 19752302.
[6]  Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68: 1412-1420. doi:10.1001/archneurol.2011.154. PubMed: 21747007.
[7]  Kim SH, Kim W, Park MS, Sohn EH, Li XF et al. (2011) Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 68: 473-479. doi:10.1001/archneurol.2010.322. PubMed: 21149806.
[8]  Twisk JW, Smidt N, de Vente W (2005) Applied analysis of recurrent events: a practical overview. J Epidemiol Community Health 59: 706-710. doi:10.1136/jech.2004.030759. PubMed: 16020650.
[9]  Marignier R, Bernard-Valnet R, Giraudon P, Collongues N, Papeix C et al. (2013) Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology 80: 2194-2200. doi:10.1212/WNL.0b013e318296e917. PubMed: 23658379.
[10]  Kim SM, Waters P, Woodhall M, Kim JY, Kim JE et al. (2013) Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders. Mult Scler, 19: 1060–7. PubMed: 23329699.
[11]  Waters P, Jarius S, Littleton E, Leite MI, Jacob S et al. (2008) Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 65: 913-919. doi:10.1001/archneur.65.7.913. PubMed: 18625857.
[12]  McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121-127. doi:10.1002/ana.1032. PubMed: 11456302.
[13]  Sormani MP, Signori A, Siri P, De Stefano N (2013) Time to first relapse as an endpoint in multiple sclerosis clinical trials. Mult Scler, 19: 466–74. PubMed: 22914849.
[14]  Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227-231. doi:10.1002/ana.410130302. PubMed: 6847134.
[15]  Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B et al. (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135: 1834-1849. doi:10.1093/brain/aws109. PubMed: 22577216.
[16]  Aalen OO (1988) Heterogeneity in survival analysis. Stat Med 7: 1121-1137. doi:10.1002/sim.4780071105. PubMed: 3201038.
[17]  Allison PD (1995) Survival analysis using the SAS system : a practical guide. Cary, NC: SAS Institute.
[18]  Guo Z, Gill TM, Allore HG (2008) Modeling repeated time-to-event health conditions with discontinuous risk intervals. An example of a longitudinal study of functional disability among older persons. Methods Inf Med 47: 107-116. PubMed: 18338081.
[19]  Hougaard P (2000) Analysis of multivariate survival data. New York: Springer.
[20]  Knaus WA, Harrell FE, Fisher CJ Jr., Wagner DP, Opal SM et al. (1993) The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis. JAMA 270: 1233-1241. doi:10.1001/jama.270.10.1233. PubMed: 8355388.
[21]  Bozdogan H (1987) Model selection and Akaike's information criterion (AIC): The general theory and its analytical extensions. Psychometrika 52: 345-370. doi:10.1007/BF02294361.
[22]  Kitley JL, Leite MI, Matthews LA, Palace J (2011) Use of mitoxantrone in neuromyelitis optica. Arch Neurol 68: 1086; author reply: 1087. doi:10.1001/archneurol.2011.170. PubMed: 21825252.
[23]  Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C et al. (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66: 1128-1133. doi:10.1001/archneurol.2009.175. PubMed: 19752302.
[24]  Cree BA, Lamb S, Morgan K, Chen A, Waubant E et al. (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64: 1270-1272. doi:10.1212/01.WNL.0000159399.81861.D5. PubMed: 15824362.
[25]  Kim SM, Waters P, Vincent A, Go MJ, Park KS et al. (2011) Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica. J Neurol 258: 2176-2180. doi:10.1007/s00415-011-6086-x. PubMed: 21594697.
[26]  Borgmann A, Schmid H, Hartmann R, Baumgarten E, Hermann K et al. (1995) Autologous bone-marrow transplants compared with chemotherapy for children with acute lymphoblastic leukaemia in a second remission: a matched-pair analysis. The Berlin-Frankfurt-Munster Study Group. Lancet 346: 873-876. doi:10.1016/S0140-6736(95)92710-7. PubMed: 7564672.
[27]  Keiding N, Andersen PK, Klein JP (1997) The role of frailty models and accelerated failure time models in describing heterogeneity due to omitted covariates. Stat Med 16: 215-224. doi:10.1002/(SICI)1097-0258(19970130)16:2. PubMed: 9004393.
[28]  Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, Amorin de Souza N, Gabbai AA (2010) Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 67: 1131-1136. doi:10.1001/archneurol.2010.203. PubMed: 20837859.
[29]  Cabre P, González-Quevedo A, Bonnan M, Saiz A, Olindo S et al. (2009) Relapsing neuromyelitis optica: long term history and clinical predictors of death. J Neurol Neurosurg Psychiatry 80: 1162-1164. doi:10.1136/jnnp.2007.143529. PubMed: 19762908.
[30]  Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53: 1107-1114. doi:10.1212/WNL.53.5.1107. PubMed: 10496275.
[31]  Wingerchuk DM, Weinshenker BG (2003) Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 60: 848-853. doi:10.1212/01.WNL.0000049912.02954.2C. PubMed: 12629245.
[32]  Sormani MP, Signori A, Siri P, De Stefano N (2013) Time to first relapse as an endpoint in multiple sclerosis clinical trials. Mult Scler 19: 466-474. doi:10.1177/1352458512457841. PubMed: 22914849.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133